A new market study, titled “Botanical and Plant-derived Drugs: Global Markets”, has been featured on WiseGuyReports.
Summary
The U.S. Food and Drug Administration’s (FDA) botanical drug pathway is still being refined as further drug candidates continue to enter the clinical development pipeline under what many consider an easier path to commercialization. FDA approval, a relatively stringent process by global standards, generally clears the path for approval in other countries. Further, the U.S. is seen as a gold standard for regulatory review.
The FDA defines botanicals drug candidates as:
– Heterogenous compositions (not well characterized) that include plant materials, algae, macroscopic fungi, or combinations thereof being tested or subsequently sold that are safe and that have clinically proven therapeutic effects.
Scope of Report
This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.
For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.
The study’s main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.
Request Sample Report at https://www.wiseguyreports.com/sample-request/2963568-botanical-and-plant-derived-drugs-global-markets
The study also does not cover the following:
– Underground or illicit drugs.
– Home remedies.
– Tribal medicines.
– Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
– Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
– Intravenously delivered nutrients of plant origin, such as dextrose.
– Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
– Plant substances serving in cosmetics, toiletries and personal care products.
– Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
– Marine life.
The format of the study is organized around the following topics:
– Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
– Industry structure.
– Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
– Market drivers.
– Market projections through 2022.
– Competition.
– Observations and conclusions regarding the future of the botanical and plant-derived drug industry.
Report Includes:
– An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
– Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
– A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address specific medical conditions or symptoms)
– Examination of the industry structure, competition, and market drivers
– Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
– Observations and conclusions regarding the future of the botanical and plant-derived drug industry.
View Detailed Report at https://www.wiseguyreports.com/reports/2963568-botanical-and-plant-derived-drugs-global-markets
Table of Contents
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Trends and Drivers for Botanical Drug Development
Chapter 3 Market and Technology Background
Brief History of Plant-Derived Medicines
Nutrition Science Partners Ltd. (Nestlé Health): A Case Study
The First and Second U.S. Approved Botanical Drug
A New Type of Production: Plant-Made Drugs
Chapter 4 Market Breakdown by Technology Type
Sales of Plant-derived Drugs by Region
Plant-derived Drugs by Therapeutic Area
Value of Plant-derived Drugs by Therapeutic Area
A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development
Chapter 5 New Developments and Market Opportunities
Hormone Therapy and Metabolism Applications
Infectious Disease Applications
Pain and Central Nervous System Disease Applications
Cardiovascular and Metabolic Applications
Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
Dermatology Applications
Gastrointestinal Applications
Oncology Applications
Botanical Drugs in Clinical Development
Promising Candidates for Botanical Drugs
Chapter 6 Company Profiles
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
